학술논문
Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.
Document Type
Article
Author
He, Lingxiao; Morley, John E.; Aggarwal, Geetika; Nguyen, Andrew D.; Vellas, Bruno; de Souto Barreto, Philipe; the MAPT/DSA Group; MAPT Study Group; Principal investigator; Coordination; Guyonnet, Sophie; Project leader; Carrié, Isabelle; CRA; Brigitte, Lauréane; Investigators; Faisant, Catherine; Lala, Françoise; Delrieu, Julien; Villars, Hélène
Source
Subject
*CYTOPLASMIC filaments
*COGNITION disorders
*HEALTH of older people
*NEURODEGENERATION
*BIOMARKERS
*
*
*
*
Language
ISSN
2045-2322
Abstract
Neurofilament light chain (NfL) has been associated with cognitive status in multiple neurodegenerative conditions. Studies about plasma NfL and cognitive decline in older adults are still limited. 504 older adults (median age 75 years) who expressed memory complaints were selected from the Multidomain Alzheimer's Preventive Trial (MAPT) and were classified as normal cognition (NC) or mild cognitive impairment (MCI). Cognitive functions were measured as mini mental state examination (MMSE) and composite cognitive score (CCS) over a 4-year period. Plasma NfL was measured at the first or the second year of the MAPT. Mixed-effects linear models were performed to evaluate cross-sectional and longitudinal associations. In the whole population, higher plasma NfL was cross-sectionally associated with lower cognitive functions (MMSE: β = − 0.007, 95% CI [− 0.013, − 0.001]; CCS: β = − 0.003, 95% CI [− 0.006, − 0.001]). In adults with MCI, but not NC, higher plasma NfL was associated with lower CCS at the cross-sectional level (β = − 0.003, 95% CI [− 0.005, − 0.0002]). The upper quartile NfL group further demonstrated more over time decline in CCS (β = − 0.07, 95% CI [− 0.12, − 0.01]) under the MCI status. Plasma NfL can be a promising biomarker of progressive cognition decline in older adults with MCI. [ABSTRACT FROM AUTHOR]